Lifesci Capital Begins Coverage on Oruka Therapeutics (NASDAQ:ORKA)

Lifesci Capital initiated coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report released on Monday, MarketBeat.com reports. The firm issued an outperform rating and a $41.00 target price on the stock.

Several other equities research analysts have also weighed in on ORKA. TD Cowen assumed coverage on Oruka Therapeutics in a report on Monday. They issued a buy rating for the company. Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a report on Friday, September 13th. They set a buy rating and a $40.00 price objective for the company. Finally, Wedbush assumed coverage on shares of Oruka Therapeutics in a report on Wednesday, September 4th. They issued an outperform rating and a $40.00 target price on the stock. Four analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Oruka Therapeutics presently has an average rating of Buy and a consensus target price of $41.25.

Oruka Therapeutics Price Performance

Shares of NASDAQ:ORKA opened at $24.82 on Monday. Oruka Therapeutics has a fifty-two week low of $18.72 and a fifty-two week high of $53.88.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.